<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hepatoid <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is a rare extra hepatic <z:hpo ids='HP_0002664'>neoplasm</z:hpo> that displays morphological and phenotypic features similar to those of <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report a case of a 75-year-old woman, presenting with <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> and complaints of <z:mp ids='MP_0000746'>weakness</z:mp> and lost of appetite, who was found to have a mass on her right colon </plain></SENT>
<SENT sid="2" pm="."><plain>She underwent right hemicolectomy for a pT3N2M0, stage IIIC <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of hepatoid origin </plain></SENT>
<SENT sid="4" pm="."><plain>The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles </plain></SENT>
<SENT sid="5" pm="."><plain>She died 1Â month later, eight months after the diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> associated with a very poor prognosis </plain></SENT>
</text></document>